[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:breast-carcinoma:brca2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Breast Carcinoma","BRCA2 Gene",22,[8,16,23,30,36,42,48,55,61,67,72,78,84,90,96,102,107,113,119,126,133,140],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03990896","Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.705241Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04150042","SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells",[20],"Phase 1","2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.297862Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06380751","Saruparib (AZD5305) Plus Camizestrant Compared With CDK4\u002F6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+\u002F ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",[27],"Phase 3","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.920406Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06488378","Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1\u002F2 and PALB2- Associated Metastatic HER2-negative Breast Cancer",[20],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.482798Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[20],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.876459Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[20],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[52],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04890613","Study of CX-5461 in Patients With Solid Tumours and BRCA1\u002F2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",[20],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.067991Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04913064","Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer",[],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.487085Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":59,"content_modified":71},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[12],"2026-07-19T19:36:05.126907Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[12],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT03729115","A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:26.901351Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study",[27],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.641158Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome",[],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.687767Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":65,"content_modified":106},"NCT06888388","Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer",[],"2026-05-13T02:55:06.588403Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT00823654","Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations",[],"2026-08-26T02:17:28.381459Z","2026-05-13T02:55:06.066613Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":117,"content_modified":118},"NCT01034033","Genetic & Pathological Studies of BRCA1\u002FBRCA2: Associated Tumors & Blood Samples",[],"2026-08-26T02:19:30.857183Z","2026-05-13T02:55:06.066896Z",{"nct_id":120,"title":121,"phases":122,"status":123,"updated_at":124,"content_modified":125},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"NOT_YET_RECRUITING","2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":127,"title":128,"phases":129,"status":130,"updated_at":131,"content_modified":132},"NCT03544983","Genetic Education in BRCA Families",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:46.951087Z","2026-06-16T05:54:07.967774Z",{"nct_id":134,"title":135,"phases":136,"status":137,"updated_at":138,"content_modified":139},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z",{"nct_id":141,"title":142,"phases":143,"status":137,"updated_at":144,"content_modified":145},"NCT04613440","FaCT Trial (Facilitated Cascade Testing Trial)",[],"2026-08-03T03:11:37.958805Z","2026-05-05T02:43:27.403661Z"]